RCM
AKTS

RA Capital Management’s Aktis Oncology AKTS Stock Holding History

RA Capital Management’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.4M Sell
1,314,405
-188,679
-13% -$3.88M 0.37% 44
2026
Q1 		$26.9M Buy
+1,503,084
New +$29.2M 0.28% 50

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RA Capital Management's AKTS Position: Q2 2026 in Review

RA Capital Management reduced its Aktis Oncology (AKTS) stake by 13% in Q2 2026, selling an estimated $3.88M and leaving 1,314,405 shares worth $42.4M. The position accounts for 0.37% of the portfolio, ranked #44.

RA Capital Management first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • RA Capital Management held 1,314,405 shares of Aktis Oncology worth $42.4M as of Q2 2026.
  • RA Capital Management sold 188,679 Aktis Oncology shares in Q2 2026, an estimated $3.88M.
  • Aktis Oncology made up 0.37% of RA Capital Management's portfolio in Q2 2026, its #44 holding.
  • RA Capital Management first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.